Enci Therapeutics

Enci Therapeutics is a biotechnology company dedicated to developing small molecule inhibitors that target the innate immune system to treat cancer. The company's core technology centers on inhibiting Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme that regulates the STING (Stimulator of Interferon Genes) pathway by degrading cGAMP. By preventing this degradation, Enci's therapeutics aim to promote an anti-tumor immune response and convert immunologically "cold" tumors into "hot" tumors. The company is leveraging research from Stanford University to advance its pipeline of ENPP1 inhibitors toward clinical trials for various solid tumor indications. Their approach seeks to overcome the limitations of direct STING agonists by modulating the natural levels of the signaling molecule cGAMP within the tumor microenvironment.